Skip to content

Lymphoedema Diagnosis and Treatment

The Role of Chat GPT in the Diagnosis and Treatment of Lymphedema

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07485465
Acronym
CDTL
Enrollment
25
Registered
2026-03-20
Start date
2026-03-15
Completion date
2026-04-01
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Artificial Intelligence (AI), Lymphedema

Keywords

lymphedema, chat gpt, artificial intelligence

Brief summary

A domain-specific, custom-trained large language model for the differential diagnosis and treatment planning of lymphedema, lipedema, and venous insufficiency.

Detailed description

The differential diagnosis of lower limb swelling remains problematic in clinical practice, as lymphedema, lipedema, and peripheral venous disease often present with similar features. Therefore, we developed LymphedemaGPT, a GPT-5-based clinical assistant designed to help practitioners navigate these diagnostic complexities. LymphedemaGPT was designed to analyze structured patient data to extract clinical summaries, present possible diagnoses with percentage probabilities, create differential diagnosis tables, suggest additional diagnostic tests, and generate evidence-based treatment plans. LymphedemaGPT's responses are based on seven scientific publications uploaded to the system, in addition to the Sleigh BC & Manna B (2023) and Rockson approaches. Owing to this resource integration, the model can provide more reliable and consistent recommendations aligned with evidence-based medicine principles based on current guidelines and scientific publications. Extensive prompt engineering techniques were applied to optimize the diagnostic and therapeutic accuracy of LymphedemaGPT. The model is programmed to prioritize the questioning phase until a diagnosis is confirmed. In the initial responses, only structured anamnesis questions were asked, and after sufficient information was collected, systematic analysis and treatment planning were initiated. The response flow was designed as follows: (1) history collection, (2) preliminary assessment, (3) additional questioning (if necessary), and (4) systematic analysis and treatment planning when sufficient data were obtained. The following patient data was presented to LymphedemaGPT in a structured format: Demographic data: Age, gender, height, weight Medical history: Additional illnesses, medications used, habits (smoking, alcohol) Complaint characteristics: Time of onset, affected area, symptoms (pain, heaviness, numbness, tingling, stiffness, limited movement, weakness, etc.) Physical examination findings: Stemmer sign, swelling change with elevation, skin findings Medical history: History of infection, history of surgery, history of malignancy (radiotherapy, chemotherapy, lymph node dissection, type of cancer) Imaging: Doppler ultrasonography and lymphoscintigraphy results, if available LymphedemaGPT was asked to respond in the following 12-part standard format: (1) Clinical Summary, (2) Possible Diagnoses (% probability), (3) Differential Diagnosis, (4) Recommended Diagnostic Tests, (5) Treatment Plan, (6) Patient Education and Follow-up, (7) Red Flags, (8) references, (9) Level of Evidence and Confidence Score, (10) Ethical Note, (11) Data Summary (JSON/CSV), and (12) Analysis Timestamp. The performance of LymphedemaGPT was evaluated by experienced physicians based on the following eight criteria: 1. Accuracy and adequacy of clinical summary 2. Accuracy of primary diagnosis 3. Accuracy of differential diagnosis table 4. Appropriateness of recommended diagnostic tests 5. Concordance of treatment plan with current guidelines 6. Appropriateness of compression class/exercise-diet recommendations 7. Adequacy of red flags 8. Overall clinical utility Each criterion was scored using a 5-point Likert scale: 5 = excellent/completely suitable, 4 = good/significantly suitable, 3 = moderate/partially suitable, 2 = poor/inadequate, and 1 = very poor/not suitable. The maximum score for each case was 40 (8 criteria × 5 points), and the minimum score was 8. Two experienced physicians independently performed the evaluation. The evaluators were physical medicine and rehabilitation specialists experienced in the management of lymphedema and lipedema, and they independently performed the scoring.

Interventions

OTHERa domain-specific, custom-trained large language model for the differential diagnosis and treatment planning of lymphedema, lipedema, and venous insufficiency

LymphedemaGPT was designed to analyze structured patient data to extract clinical summaries, present possible diagnoses with percentage probabilities, create differential diagnosis tables, suggest additional diagnostic tests, and generate evidence-based treatment plans.

Sponsors

Fatih Sultan Mehmet Training and Research Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over the age of 18 * Clinical diagnosis of lymphoedema * Clinical diagnosis of lipoedema * Clinical diagnosis of venous insufficiency

Exclusion criteria

* Lack of medical history * Lack of demographic data * Lack of clinical data and * Lack of imaging methods

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic accuracy rate1 hourPercentage of cases where the primary diagnosis (most likely diagnosis) was correctly determined. The maximum percentage for each case was 100, and the minimum percentage was 0. Higher percentages mean a better outcome.
Treatment adequacy rate1 hourPercentage of treatment recommendations consistent with current guidelines. The maximum percentage for each case was 100, and the minimum percentage was 0. Higher percentages mean a better outcome.
Average criterion score1 hourAverage Likert score of two evaluators for each criterion. The maximum score for each case was 40, and the minimum score was 8. higher scores mean a better outcome.

Secondary

MeasureTime frameDescription
Overall performance score1 hourOverall average of all criteria and cases. The maximum score for each case was 40, and the minimum score was 8. higher scores mean a better outcome.

Countries

Turkey (Türkiye)

Contacts

CONTACTYunus Emre Doğan, MD
ynsemredgn91@gmail.com+90 506 051 25 00
PRINCIPAL_INVESTIGATORYunus Emre Doğan, MD

Istanbul Fatih Sultan Mehmet Training and Research Hospital

STUDY_CHAIRFeyza Akan Begoğlu, MD

Istanbul Fatih Sultan Mehmet Training and Research Hospital

STUDY_CHAIRMesut Canlı, MD

Istanbul Fatih Sultan Mehmet Training and Research Hospital

STUDY_CHAIRİlknur Aktaş, MD, Prof.

Istanbul Fatih Sultan Mehmet Training and Research Hospital

STUDY_CHAIRFeyza Ünlü Özkan, MD, Prof.

Istanbul Fatih Sultan Mehmet Training and Research Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026